Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Correspondence and requests for materials should be addressed to D.Y., H.E.X., Y.Z
The GIP component appears to blunt GLP-1-associated nausea, which is one reason discontinuation rates for tirzepatide are lower than for pure GLP-1 agonists at equivalent weight-loss doses [1]
Not practical for most users
Important Regulatory & Legal Notice Research & Development Use Only: This product is supplied strictly for laboratory research, analytical testing, and scientific evaluation
The subcutaneous injections available in the United States are dulaglutide (Trulicity, Eli Lilly, for type 2 diabetes), liraglutide (Victoza, Novo Nordisk, for type 2 diabetes), semaglutide (Ozempic, Novo Nordisk, for type 2 diabetes and Wegovy, for weight loss), tirzepatide (Mounjaro, Eli Lilly, for type 2 diabetes), and Zepbound (Eli Lilly, for weight loss)
US$ 26.05
US$ 22.98
US$ 21.50
